8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 21, 2007

DATASCOPE CORP.

(Exact name of registrant as specified in its charter)

Delaware	0-6516	13-2529596
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)
14 Philips Parkway
Montvale, New Jersey		07645-9998
(Address of principal executive offices)		(Zip Code)

(Registrant’s telephone number, including area code): (201) 391-8100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

          The Board of Directors of Datascope Corp. (the “Company”) appointed Dr. Antonino Laudani as Chief Operating Officer of the Company effective October 21, 2007. Dr. Laudani, 48, has been employed by the Corporation as Vice President; Group President, Cardiac Assist and InterVascular from June 2007 to October 2007, and President, InterVascular, Inc. since February 2005. From January 2005 to April 2005, he was Group Vice President of Sales for Cardiac Assist, InterVascular and Interventional Products for Europe, the Middle East and Africa (“EMEA”). From May 2002 to December 2004, Mr. Laudani served as Vice President, Cardiac Assist Sales for EMEA. Prior to joining the Corporation, Mr. Laudani was an independent consultant from February 2002 to April 2002. Mr. Laudani served as Vice President Marketing for Tyco Healthcare for EMEA from June 1999 to January 2002. In this position, Mr. Laudani was also in charge of R&D and non-hospital product sales for EMEA.

          The Board of Directors also approved an increase in Dr. Laudani’s salary to 370,000 Euros per year and a grant of 50,000 shares of restricted stock, which will vest in 25% increments on each of the first four anniversaries of the grant date, subject to Dr. Laudani’s continued employment through each applicable vesting date, and he is eligible to receive a bonus equal to 250,000 Euros, or 68% of his base salary, pursuant to the 2005 Management Incentive Plan.

          On October 22, 2007, the Company issued a press release announcing the matters discussed above. The press release is attached as Exhibit 99.1 to this report.

Item 9.01 Exhibits.

     (c)  Exhibits:

Exhibit 99.1      Press release announcing the appointment of Dr. Antonino Laudani as Chief Operating Officer, effective October 21, 2007.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

DATASCOPE CORP.

Registrant
 

/s/ Henry M. Scaramelli  

     Vice President, Finance and 

     Chief Financial Officer 

Dated: October 24, 2007

EXHIBIT INDEX

Exhibit 99.1       Press release announcing the appointment of Dr. Antonino Laudani as Chief Operating Officer, effective October 21, 2007.

EX-99.1

Exhibit No. 99.1

PRESS RELEASE
For Information Contact:
Henry Scaramelli
Chief Financial Officer
Datascope Corp.
(201) 307-5435
www.datascope.com

FOR IMMEDIATE RELEASE:

Datascope Names Chief Operating Officer

MONTVALE, N.J., Oct 22, 2007...Datascope Corp. (NASDAQ: DSCP) announced today that Dr. Antonino Laudani was named Chief Operating Officer (COO), effective October 21, 2007, pursuant to a Board action in September that approved the establishment of the COO executive position and the promotion of Dr. Laudani to that post. Dr. Laudani reports to CEO Lawrence Saper.

The Company expects the COO position to strengthen its core management structure and, due to Dr. Laudani’s extensive international experience, add considerable global expertise to top management.

Dr. Laudani was chosen as COO because he has been consistently successful in managing major business assignments since he joined Datascope more than five years ago. Starting as VP for Europe, Middle East and Africa (EMEA) for Cardiac Assist products, he reorganized the sales and clinical teams to achieve remarkable results in growing the utilization of counterpulsation therapy. In June 2004, given the sales and marketing responsibility for two other divisions, InterVascular and Interventional, Dr. Laudani proposed and implemented the combination of separate sales forces and clinical resources to create the EMEA Group, a single integrated sales, clinical and marketing group to sell the products of three divisions. Since its formation two and one-half years ago, the EMEA Group has delivered significant compounded growth in sales and profits through fiscal 2007. In February 2005, Laudani took on the additional post of President of our InterVascular company, where he succeeded in turning around a downward trend of sales and earnings by increasing market share, reducing selling costs and revamping its manufacturing operation to reduce product cost and improve quality. A little over one year ago, he began the integration of Patient Monitoring products into the EMEA Group, this time using the existing dedicated direct sales forces in the major European markets, but with reporting lines to country managers common to the EMEA Group.

Dr. Laudani has also been active in business development, acquiring distribution rights and a purchase option for the Sorin carbon-coated peripheral stent product line that has been contributing to EMEA sales and margin since mid-fiscal 2007.

Dr. Laudani received an M.D. degree cum laude from the University of Catania, Italy in 1983 and spent an additional two years in internship, after which he chose a professional career in the

medical products business. Over a 17-year span, prior to joining Datascope, Dr. Laudani worked for two major health care companies, spending three years at Tyco Healthcare Europe, where he was VP Marketing and R&D for Tyco’s medical product line, and 14 years at Johnson & Johnson Medical during which time he advanced with distinction to European Marketing Director for J&J Medical Europe.

About Datascope

Datascope Corp. is the global leader of intra-aortic balloon counterpulsation and a diversified medical device company that develops, manufactures and markets proprietary products for clinical health care markets in interventional cardiology and radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical care. The Company’s products are sold throughout the world through direct sales representatives and independent distributors. Founded in 1964, Datascope is headquartered in Montvale, New Jersey. For news releases, webcasts and other Company information please visit Datascope’s website, www.datascope.com.